State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People’s Republic of China
Auto-generated profile, based on publicly available information
Bin Zhou
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, People’s Republic of China
This study represents a systematic chemical and biological study of the rufomycin (RUF) class of cyclic heptapeptides, which our anti-TB drug discovery efforts have identified as potentially promising anti-TB agents that newly target the caseinolytic protein C1, ClpC1. Eight new RUF analogues, rufomycins NBZ1–NBZ8 (1–8), as well as five known peptides (9–13) were isolated and characterized from the Streptomyces atratus strain MJM3502. Advanced Marfey’s and X-ray crystallographic analysis led to the assignment of the absolute configuration of the RUFs. Several isolates exhibited potent activity against both pathogens M. tuberculosis H37Rv and M. abscessus, paired with favorable selectivity (selectivity index >60), which collectively underscores the promise of the rufomycins as potential anti-TB drug leads.
Four new lindenane sesquiterpenoid trimers, designated as trichloranoids A–D (1–4), along with a known analogue (5) were isolated from Chloranthus spicatus. Their structures were elucidated by a combination of diverse methods, including DP4+ probability and TDDFT-ECD calculations. Compounds 1 and 2 incorporated one unprecedented skeletal unit respectively in their western hemisphere, and each of them was likely formed biogenetically via a biradical rearrangement of the vinylcyclopropane. Compounds 1, 4, and 5 exhibited moderate antimalarial activities.
We describe a novel collaboration between academia and industry, an in-house data science and artificial intelligence challenge held by Novartis to develop machine-learning models for predicting drug-development outcomes, building upon research at MIT using data from Informa as the starting point. With over 50 cross-functional teams from 25 Novartis offices around the world participating in the challenge, the domain expertise of these Novartis researchers was leveraged to create predictive models with greater sophistication. Ultimately, two winning teams developed models that outperformed the baseline MIT model—areas under the curve of 0.88 and 0.84 versus 0.78, respectively—through state-of-the-art machine-learning algorithms and the use of newly incorporated features and data. In addition to validating the variables shown to be associated with drug approval in the earlier MIT study, the challenge also provided new insights into the drivers of drug-development success and failure.